The outbreak of the COVID-19 pandemic caused the healthcare system to drastically reduce in-person visits and suddenly switch to telemedicine services to provide clinical care to patients. The implementation of teleconsultation in medical facilities was a novelty for most Polish patients. In Poland, the main telehealth services were provided in the form of telephone consultations. The aim of this study is to determine patients’ perceptions of telemedicine in the context of their experiences with the healthcare system during the COVID-19 pandemic. In this study, we presented how the evaluation of telemedicine services from the perspective of patients in Poland changed in the context of the ongoing pandemic. We conducted two surveys (year by year) on a representative quota sample of the Polish population (N = 623). This ensured that our observations took into account the evolution of views on telemedicine over time. We confirmed the well-known relationship that innovations introduced in the healthcare sector require a longer period of adaptation. We also identified significant concerns that limit the positive perception of telemedicine and compared them with experiences described in other countries.
In the present study, we aimed to assess the anti-SARS-CoV-2 antibodies in population or in convalescents 6 months after infection with COVID-19. The study population consisted of 2 groups, i.e. group I: 232 post-COVID-19 patients, and group II: 544 patients from a population cohort. Detection of anti-N antibodies was performed with Elecsys Anti-SARS-CoV-2 and anti-S antibodies with LIAISON SARS-CoV-2 S1/S2 IgG tests. After the Omicron wave, gradual increase in the prevalence of the analyzed antibodies was observed in the general population - up to 92.5% of anti-S and 69.7% of anti-N antibodies. In the COVID-19 convalescents, 6 months after infection, 4.3% and 3.7% did not generate significant titer of anti-S and anti-N antibodies, respectively. Among patients, who were vaccinated, 1% did not generate anti-S antibodies. Median age of those who did not respond was higher than those who responded. Sex did not influence the results. Comparison of anti-N and anti-S antibodies 6 months after infection in the whole group showed higher anti-N titer in patients who suffered from the disease than in the general population. In the general population, 17.4% of participants had anti-N antibodies, and 9% had anti-S antibodies, despite no prior vaccination or history of COVID-19. High prevalence of anti-N antibodies in patients reporting no history of COVID-19 during last wave, even after official end of the pandemics suggests high prevalence of SARS-CoV-2 in the environment and frequent asymptomatic or unspecific COVID-19, what is of high importance from the public health perspective.
The coronavirus disease 2019 pandemic created a significant crisis in global health. The aim of the study was to compare the impact of the COVID-19 pandemic on self-rated health status and smoking and alcohol habits. The Bialystok PLUS cohort study was conducted in 2018–2022. A total of 1222 randomly selected city residents were examined and divided into two groups: before and during the COVID-19 pandemic. The participants’ lifestyle habits and medical history were collected from self-reported questionnaires. The Alcohol Use Disorders Identification Test (AUDIT) and the Fagerström Test for Nicotine Dependence (FTND) were used to assess the degree of alcohol and nicotine dependence. The survey revealed a reduced frequency of reported allergies vs. an increased frequency of reported sinusitis and asthma; increased incidence of declared hypercholesterolemia and visual impairment; a reduced number of cigarettes smoked per day, lower FTND score, and a greater desire to quit smoking in the next six months; and an increase in hs-CRP and FeNO levels in the population during the pandemic compared to the pre-pandemic population. The COVID-19 pandemic had a measurable impact on the general population’s prevalence of certain medical conditions and lifestyle habits. Further research should continue to examine the long-term health implications of the pandemic.
Introduction: Smoking cigarettes is widely recognized as a significant risk factor for tooth loss. Objectives: The aim of this study was to assess the association between cigarette smoking, smoking cessation, and the number of remaining teeth in an adult population. Methods: Data from the Bialystok Plus population study, collected between November 2018 and January 2024, were analyzed. Participants were stratified into young (20–44 years), middle-aged (45–64 years), and older (65 years and above) groups. The outcome was the number of lost teeth. Smoking status (non-smoker vs. ever smoker and former smoker vs. current smoker) and smoking duration were the main independent variables. Additional variables included age, sex, dental habits and medical history. Risk factor analysis was done with generalized linear models using the negative binomial family. Results: Ever smoking was significantly associated with tooth count. Differences in the number of remaining teeth between former and current smokers were observed across age groups but not in the overall population. Current smokers exhibited a significantly greater decline in the number of teeth with an increasing fraction of life spent smoking compared to former smokers. Negative binomial regression models showed that ever smoking, when adjusted for age and diabetes, was a risk factor of tooth loss, but a protective effect of smoking cessation was not confirmed. Conclusions: This study confirmed that tobacco addiction is associated with tooth loss. Being a current smoker remained non-significant as a risk factor for tooth loss when compared to former smoker status.
Background/Objectives: Post-COVID-19 condition involves heterogeneous, multisystem symptoms with uncertain recovery. We characterized symptom trajectories from hospitalization to approximately 4 weeks and to 6–8 months and compared the 6–8-month symptom burden with season-matched controls, accounting for serology-identified, previously unrecognized infections. Methods: An individually pair-matched case–control study of adults with RT-PCR–confirmed SARS-CoV-2 and population controls from the Bialystok PLUS cohort, matched on age, sex and a two-month visit window, was performed. All participants underwent anti-nucleocapsid serology. Hospitalized cases were reassessed at approximately 4 weeks and 6–8 months. Cross-sectional outcomes used non-parametric tests and multivariable regression; longitudinal change used paired tests and generalized estimating equations. Results: We included 402 adults (201 post-COVID-19; 201 controls). In hospitalized cases, respiratory symptoms declined rapidly by approximately 4 weeks and remained low at 6–8 months; smell/taste recovered more slowly; fatigue improved modestly; anxiety changed minimally. At 6–8 months, total symptom counts were higher in post-COVID-19 than in controls (median 4 vs. 2), with serology-positive controls intermediate (median 3). Excess burden was concentrated in non-respiratory domains (fatigue, neurocognitive, cardiovascular, and dermatologic), whereas respiratory differences were not significant. In the multivariable model, female sex remained an independent predictor of higher multisystem burden, whereas age, body mass index, hospitalization, and acute biomarker severity were not associated. Conclusions: Six to eight months after symptomatic COVID-19, multisystem symptom burden remains substantial relative to season-matched controls, despite substantial resolution of respiratory complaints. Serology-based identification of previously unrecognized infections indicates an intermediate burden and can guide targeted follow-up.
Background: In the post-pandemic era, SARS-CoV-2 immunity is increasingly shaped by vaccination and previous infection. Understanding the relationship between cellular and humoral immune responses is important for characterizing immunity in vaccinated populations. Methods: This study included 629 participants from the Bialystok PLUS cohort, stratified according to anti-N serostatus into anti-N-seronegative (n = 159) and anti-N-seropositive (n = 470) groups. Cellular immune response measurements were available for a subset of 246 participants. Humoral response was assessed using anti-S and anti-N antibodies, while cellular response (OC) was evaluated by interferon-gamma (IFN-γ) release following SARS-CoV-2 antigen stimulation. Group differences were assessed using the Mann–Whitney U test, and associations were evaluated using Spearman’s rank correlations with Benjamini–Hochberg correction. Multivariable linear regression was used to assess the association between anti-N serostatus and cellular response after adjustment for age and sex. Results: Anti-N-seropositive participants had significantly higher cellular responses than anti-N-seronegative participants (median 1752.3 vs. 771.1; p < 0.001). After adjustment for age and sex, anti-N seropositivity remained significantly associated with higher cellular response, corresponding to a 3.57-fold higher geometric mean of OC + 1 (95% CI: 1.90–6.73; p < 0.001). Anti-S antibody levels showed moderate positive correlations with cellular response in both anti-N-seronegative and anti-N-seropositive participants (ρ = 0.45 and ρ = 0.37, respectively), and the association remained significant after adjustment for age, sex, and anti-N serostatus. No significant associations were observed between cellular response and anti-N antibody levels or routine laboratory parameters after correction for multiple comparisons. Conclusions: Anti-N seropositivity was associated with higher SARS-CoV-2-specific cellular immune response among vaccinated participants, and this association remained significant after adjustment for age and sex. The moderate association between anti-S antibody levels and cellular response suggests that humoral and cellular measures provide related but complementary information on SARS-CoV-2-specific immunity. Routine laboratory parameters were not significantly associated with cellular immune response in this cohort.